Clinical trial
EMPA-TROPISM Trial: Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity?
NCT03485222 is registered in ClinicalTrials.gov with Icahn School of Medicine at Mount Sinai as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- EMPA-TROPISM Trial: Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity?
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 21, 2018
- Completion date
- February 13, 2020
- Enrollment
- 84 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.